Medicine
Apretude kit
Apretude kit is a prescription medicine containing Cabotegravir, marketed by ViiV Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Do not freeze. If the pack has been stored in the refrigerator, the vial…
Key facts
- Active ingredient (INN)
- Cabotegravir
- Brand
- Apretude
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- ViiV Healthcare
- Manufacturer
- ViiV Healthcare
- Origin register
- US FDA, United States
- Storage
- Do not freeze. If the pack has been stored in the refrigerator, the vial should be brought to room temperature prior to administration (not to exceed 30°C [86°F]). The filled syringes should not be placed in the refrigerator. Store APRETUDE at 2°C to 25°C (36°F to 77°F) in the original carton until ready to use. Exposure up to 30°C permitted.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AJ04 Cabotegravir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 December 2021
- Identifiers
- RxCUI 2588077, 2588080DailyMed set ID 4338428e-43d4-4e02-ac9d-bd98e738a7daNDC 49702-280, 49702-264Application NDA215499
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 3 mL in 1 vial | 49702-264-23 | ViiV Healthcare | 20 December 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Cabotegravir
Clinical summary
Cabotegravir is a human immunodeficiency virus integrase strand transfer inhibitor indicated in combination with EDURANT (rilpivirine) for short-term treatment of HIV-1 infection in adults, among other approved uses. MedsAcross supplies Cabotegravir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CabotegravirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Vocabria prescribing information (ViiV Healthcare) · U.S. National Library of Medicine, DailyMed
- Apretude: European public assessment report (EPAR) · European Medicines Agency
- Vocabria: European public assessment report (EPAR) · European Medicines Agency
Need Apretude kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.